Ratcliffe Liam
SEC-identified person · CIK 1547100 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Gemini Therapeutics, Inc. /DE IRON | Director | filed 2023–2026 |
| Upstream Bio, Inc. UPB | Director | filed 2024–2026 |
| Reneo Pharmaceuticals, Inc. RPHM | Director | filed 2026–2026 |
| Eliem Therapeutics, Inc. ELYM | Director | filed 2021–2024 |
| Arvinas, INC. AVRN | Director | filed 2018–2022 |
| Passage BIO, Inc. PASG | Director | filed 2020–2021 |
| Unum Therapeutics, Inc. UNUM | Director | filed 2018–2019 |
| Aptinyx Inc. APTX | Director | filed 2018–2019 |
| PDS Biotechnology Corp PDSB | Director | filed 2016–2019 |
| Iterum Therapeutics plc ITRM | Officer | filed 2018–2018 |
| Deciphera Pharmaceuticals, Inc. NA | Director | filed 2017–2018 |
| Irhythm Technologies, Inc. IRTC | Officer | filed 2016–2016 |
| MEI Pharma, Inc. MSHL | Officer | filed 2013–2015 |
| Versartis, Inc. VSAR | Officer | filed 2014–2014 |
| Durata Therapeutics, Inc. DRTX | Officer | filed 2014–2014 |
| Chimerix INC CRMX | Officer | filed 2014–2014 |
| Concert Pharmaceuticals, INC. N/A | Officer | filed 2014–2014 |
| Oxford Immunotec Global PLC OXFD | Officer | filed 2013–2013 |
| Relypsa Inc RLYP | Officer | filed 2013–2013 |
| Array Biopharma INC ARRY | Director | filed 2012–2013 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.